MindMed readying Phase III trials for LSD therapy to treat anxiety

By / / Finance / 1 minute of reading



im 00030255
MindMed Inc. said Tuesday it’s on track to launch Phase 3 clinical trials with up to 440 people starting later this year for its treatment of generalized anxiety disorder (GAD) through use of lysergide D-tartrate (LSD) in a clinical setting.



Source link

About The Author

Avatar of Shana Hull
Shana Hull is a professional writer, editor, and interviewer. She's written for a variety of publications in the arts, construction, automotive, travel, real estate, and fashion industries. Shana has also worked as a content strategist for several companies in the finance and technology sectors.

Start typing and press enter to search

Scroll to Top